The prediction is adjusted downward due to consistent net losses over the last three fiscal years and a neutral review. Despite high revenue growth in 2025, the lack of institutional subscription data and negative PAT margins create a risk-averse listing environment.
💪 Strengths
Rapid revenue growth from ₹119.12 Cr in 2024 to ₹693.21 Cr in 2025
Comprehensive product suite including insurance, mutual funds, and loans
⚠️ Weaknesses
Consistent net losses over multiple years
Negative Return on Net Worth (RoNW) of 47.29%
🚀 Opportunities
Expansion of digital insurance penetration in the Indian market
Scaling technology and product development teams with fresh IPO funds
🛡️ Threats
Intense competition from other established fintech and insurtech players
Sustainability of high growth rates without achieving profitability
🎯 Objectives of the IPO
Requirement / Purpose
Amount (₹ Cr)
Expenditure towards cloud and server related infrastructure of the Company;
₹25.64
Salary expenditure towards the technology and product development teams of the Company;
₹193.04
Expenditure towards marketing initiatives by the Company;
₹39.07
Expenditure towards lease payments for existing properties of the Company and wholly owned Subsidiary, TIB, breakup of which is as follows: Expense by the Company
₹22.21
Expenditure towards lease payments for existing properties of thr Company and wholly owned Subsidiary, TIB, breakup of which is as follows: Expense by wholly owned Subsidiary, TIB
₹20.87
Investment in the wholly owned Subsidiary, TIB, for funding its working capital requirements; and
₹128.64
Funding inorganic growth through unidentified acquisitions and strategic initiatives and general corporate purposes.
This issue is managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd.
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.